Literature DB >> 10622472

Poor survival of cementless Biomet total hip: a report on 1,047 hips from the Finnish Arthroplasty Register.

T J Puolakka1, K J Pajamäki, P O Pulkkinen, J K Nevalainen.   

Abstract

In Finland, almost 50% of all hip replacements done after 1989 have been inserted without cement. Biomet components have been the most commonly used implants in cementless arthroplasties. Between 1985 and 1997, 4,300 prostheses were implanted because of primary osteoarthrosis. 4 different acetabular component designs have been identified as Biomet implants (Mallory-Head, Romanus, T-TAP, Universal) and were used in 1,047 hips. The 9-year survival of all arthroplasties using Biomet cups was only 65 (95% CI 61-69)% while that of arthroplasties using T-TAP-cups was only 58 (52-65)%. In contrast, the 7.5-year survival of arthroplasties using Romanus cups was 85 (79-91)%. The 98 (96-99)% 5-year survival of arthroplasties with Mallory-Head cups should be interpreted cautiously, since similar results of arthroplasties using the Universal cup with the same type of liner decline sharply to 93 (88-98)% only 1 year later. The poor survival of Biomet cementless prostheses in our series seems to be related to the poor survival of the cup. This finding was common to all metal shell designs using Hexloc liners. We recommend that Biomet cups with Hexloc liners should not be used and patients who have had them inserted should undergo regular clinical and radiographic follow-ups.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10622472     DOI: 10.3109/17453679909000975

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  11 in total

1.  Increased volumetric wear of polyethylene liners with more than 3 years of shelf-life time.

Authors:  T J S Puolakka; J T Keränen; K A Juhola; K J J Pajamäki; P J Halonen; J K Nevalainen; V Saikko; M U K Lehto; M Järvinen
Journal:  Int Orthop       Date:  2003-04-01       Impact factor: 3.075

2.  Editorial: Our love affair with technology and the choices we make.

Authors:  Seth S Leopold
Journal:  Clin Orthop Relat Res       Date:  2014-08-07       Impact factor: 4.176

3.  Cementless total hip arthroplasty for primary osteoarthritis in patients aged 55 years and older.

Authors:  Keijo T Mäkelä; Antti Eskelinen; Pekka Paavolainen; Pekka Pulkkinen; Ville Remes
Journal:  Acta Orthop       Date:  2010-02       Impact factor: 3.717

4.  Uncemented and cemented primary total hip arthroplasty in the Swedish Hip Arthroplasty Register.

Authors:  Nils P Hailer; Göran Garellick; Johan Kärrholm
Journal:  Acta Orthop       Date:  2010-02       Impact factor: 3.717

5.  Survival of Bi-Metric femoral stems in 77 total hip arthroplasties for juvenile chronic arthritis.

Authors:  C C Lybäck; C O Lybäck; A Kyrö; H J Kautiainen; E A Belt
Journal:  Int Orthop       Date:  2004-08-14       Impact factor: 3.075

6.  The Bimetric cementless total hip replacement: 7-18 year follow-up assessing the influence of acetabular design on survivorship.

Authors:  R C Russell; A Ghassemi; J H Dorrell; D P Powles
Journal:  Int Orthop       Date:  2008-06-13       Impact factor: 3.075

7.  Effects of hydroxyapatite coating of cups used in hip revision arthroplasty.

Authors:  Stergios Lazarinis; Johan Kärrholm; Nils P Hailer
Journal:  Acta Orthop       Date:  2012-09-03       Impact factor: 3.717

8.  The Ringloc liner compared with the Hexloc liner in total hip arthroplasty.

Authors:  Sköldenberg Olof; Salemyr Mats; Muren Olle; Johansson Ake; Ahl Torbjörn; Bodén Henrik
Journal:  Orthop Rev (Pavia)       Date:  2009-10-10

9.  No improvement in long-term wear and revision rates with the second-generation Biomet cup (RingLoc) in young patients: 141 hips followed for median 12 years.

Authors:  Bart Boesenach; Huub J L van der Heide; Rob G H H Nelissen
Journal:  Acta Orthop       Date:  2011-11-09       Impact factor: 3.717

10.  Increased risk of revision of acetabular cups coated with hydroxyapatite.

Authors:  Stergios Lazarinis; Johan Kärrholm; Nils P Hailer
Journal:  Acta Orthop       Date:  2010-02       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.